1. Home
  2. SKYE vs FINS Comparison

SKYE vs FINS Comparison

Compare SKYE & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • FINS
  • Stock Information
  • Founded
  • SKYE 2012
  • FINS 2019
  • Country
  • SKYE United States
  • FINS United States
  • Employees
  • SKYE N/A
  • FINS N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • FINS Finance/Investors Services
  • Sector
  • SKYE Health Care
  • FINS Finance
  • Exchange
  • SKYE Nasdaq
  • FINS Nasdaq
  • Market Cap
  • SKYE 176.8M
  • FINS 311.3M
  • IPO Year
  • SKYE N/A
  • FINS N/A
  • Fundamental
  • Price
  • SKYE $5.89
  • FINS $12.60
  • Analyst Decision
  • SKYE Strong Buy
  • FINS
  • Analyst Count
  • SKYE 4
  • FINS 0
  • Target Price
  • SKYE $19.25
  • FINS N/A
  • AVG Volume (30 Days)
  • SKYE 386.3K
  • FINS 78.0K
  • Earning Date
  • SKYE 01-01-0001
  • FINS 01-01-0001
  • Dividend Yield
  • SKYE N/A
  • FINS 9.97%
  • EPS Growth
  • SKYE N/A
  • FINS N/A
  • EPS
  • SKYE N/A
  • FINS N/A
  • Revenue
  • SKYE N/A
  • FINS N/A
  • Revenue This Year
  • SKYE N/A
  • FINS N/A
  • Revenue Next Year
  • SKYE N/A
  • FINS N/A
  • P/E Ratio
  • SKYE N/A
  • FINS N/A
  • Revenue Growth
  • SKYE N/A
  • FINS N/A
  • 52 Week Low
  • SKYE $1.44
  • FINS $11.61
  • 52 Week High
  • SKYE $19.41
  • FINS $12.57
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 34.36
  • FINS 63.05
  • Support Level
  • SKYE $5.95
  • FINS $12.42
  • Resistance Level
  • SKYE $6.83
  • FINS $12.70
  • Average True Range (ATR)
  • SKYE 0.82
  • FINS 0.14
  • MACD
  • SKYE 0.09
  • FINS 0.02
  • Stochastic Oscillator
  • SKYE 21.26
  • FINS 75.00

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest

Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.

Share on Social Networks: